allopurinol/kanker

Tautan disimpan ke clipboard

Pilih jenis pengurutan

Halaman 1 dari 35 hasil

The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Phase 1 The Phase 1 portion of the study will enroll patients into a 3+3 dose-escalation design to assess the dose-limiting toxicities (DLTs) and establish an Maximum tolerated dose (MTD)/Recommended Phase 2 does (RP2D). Up to 9 sequential AVM0703 dose cohorts are planned. In each cohort, 3 to 6

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

This is a single-center phase II study using bendamustine-rituximab (BR) followed by venetoclax and rituximab for the upfront treatment of chronic lymphocytic leukemia (CLL). The activity, safety, and survival data have been presented previously for BR alone in patients with previously untreated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

This is an open-label, multi-center, single arm phase II trial, with a two-stage design, to evaluate the activity and safety of ABT-199 single agent in patients with BCL-2 pos R/R PTCL-NOS, AITL, TFH. A pre-screening evaluation of immunohistochemical positivity of BCL-2 will be performed in the

The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

The background and rationale The extended 2016 EULAR updated report states [2] that for patients on ULT, SUA level should be monitored and maintained to <6 mg/dL (360 µmol/L). A lower SUA target (<5 mg/dL; 300 µmol/L) to facilitate faster dissolution of crystals is recommended for patients with

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Tumor heterogeneity leads to a significant difference in the rate of response to drugs in patients with the same pathological type. According to the information, the current initial effective rate of domestic and foreign chemotherapeutic single drug is no more than 30%, even if treated with repeated

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen with the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403. II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

- Patients will have several visits to the Pediatric Oncology outpatient clinic. Each visit will consist of a physical examination and laboratory evaluation. Each laboratory evaluation will consist of taking approximately 10 to 15 milliliters of blood (or approximately three teaspoons). These clinic

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

STUDY OBJECTIVE The objective of this study is to evaluate the safety, tolerability and efficacy of G-FLIP (Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin), when used in combination with ascorbic acid (Vitamin C), as first-line therapy in patients with advanced

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Heavy Water Administration: If you are found to be eligible to take part in this study, you will receive heavy water to drink for 4 weeks. The vials of heavy water will be shipped to your home location. On Days 1-5, you will drink the heavy water 3 times each day. You will drink 1 dose in the

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 24 patients will be enrolled in Part 1 of the study and up to 44 participants will be enrolled in Part 2. If you are enrolled in Part 1, the dose

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

This study is designed as a randomised, double-blind, active-controlled, parallel-group study to be conducted in approximately 80 sites. Approximately 340 male or female patients aged 18 or older suffering from hematologic malignancies (de novo patients or relapsing patients) at intermediate to high

Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Previously, some of the cancer cells were taken from the subject's body and separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put into the cells. Adenovirus is a common virus found in human respiratory systems. In its normal state, it can

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

PRIMARY OBJECTIVES: I. To prospectively evaluate the efficacy, as defined by uric acid response rate, of 2 different single low doses of rasburicase followed by allopurinol in 2 treatment arms. SECONDARY OBJECTIVES: I. To estimate the proportion of patients requiring additional doses of rasburicase

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Study Drug Administration: If you are found to be eligible to take part in this study, you will receive rituximab by vein on Days 1, 8, 15, and 22 of Cycle 1 (+ 3 days) and then on Day 1 (+/- 7 days) of Cycles 2-6. Each cycle is 28 days. You will take Ibrutinib capsules by mouth 1 time each day

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Study Drug Administration: If you are found to be eligible to take part in this study, you will begin taking the study drugs in 28-day cycles. One time a week during Cycle 1, you will receive rituximab by vein. During Cycle 2, you will not receive rituximab. During Cycles 3-12, you will receive

Sebelumnya
1
2
3
Lanjut

Bergabunglah dengan
halaman facebook kami

Herbal & Natural Medicine

Database tanaman obat terlengkap yang didukung oleh sains

Bekerja dalam 55 bahasa
Pengobatan herbal didukung oleh sains
Pengenalan herbal melalui gambar
Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
Baca publikasi ilmiah yang terkait dengan pencarian Anda
Cari tanaman obat berdasarkan efeknya
Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten

Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan